Robot-assisted nephroureterectomy for upper tract urothelial carcinoma: the Taiwan Robot Urological Surgery Team (TRUST) experience

World Journal of Surgical Oncology

Research

Yeong-Shiau Pu¹  Chao-Yuan Huang¹  Shiu-Dong Chung²  Shun-Fa Hung²  Wei-Che Wu²  Yen-Chuan Ou³  Chen-Kuang Yang³ 

[1] Department of Urology, School of Medicine, College of Medicine, National Taiwan University, 1 Roosevelt Road, 10617, Taipei, Taiwan;Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Nanya South Road, 220, New Taipei City, Taiwan;Division of Urology, Department of Surgery, Taichung Veterans General Hospital, 1650 Taiwan Boulevard, 40705, Taichung, Taiwan;

关键词: Urothelial carcinoma;    Kidney;    Ureter;    Robot;    Laparoscopy;   

DOI  :  10.1186/1477-7819-12-219

 received in 2014-01-01, accepted in 2014-07-04,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundTo report Taiwan’s experience in robot-assisted laparoscopic nephroureterectomy (RANU) for upper tract urothelial carcinoma (UTUC).MethodsTwenty patients with a diagnosis of renal pelvic or ureteral urothelial carcinoma underwent RANU at three medical centers. We performed RANU by re-docking the robot after the nephrectomy with or without repositioning for excision of the distal ureter and bladder cuff.ResultsFrom November 2010 to July 2013, a total of 20 patients with a mean age of 70.1 +/- 9.9 years (range 43 to 92 years) and mean body mass index (BMI) of 22.9 +/-3.8 kg/m2 underwent RANU for renal pelvic or ureteral urothelial carcinoma. Mean operative time was 251.6 +/- 126.7 minutes (range 110 to 540 minutes), estimated blood loss was 50.0 +/- 42.9 mL (range 10 to 200 mL), and mean length of hospital stay was 6.7 +/- 2.4 days (range 4 to 12 days). Pathology data revealed 19 high and one low-grade urothelial carcinoma and staged Ta for three, T1 for five, T2 for five and T3 for seven. With a mean follow-up of 14.7 months (range 2 to 34 months), three intravesical recurrences developed in the bladder, and four of them also developed metastatic disease.ConclusionsThe TRUST early experience showed that RANU is a safe and feasible minimally invasive procedure for UTUC.

【 授权许可】

Unknown   
© Yang et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.